An FDA-approved drug to lower blood sugar in adults with Type 2 diabetes also may decrease blood vessel dysfunction associated with aging, according to a new study from the University of Missouri School of Medicine.
Researchers initially examined the role aging plays in human blood vessel function and stiffness. Then they evaluated how treatment with the sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Empa) improved blood vessel function and reduced arterial stiffness in aged male mice.
“Cardiovascular disease is the main cause of death in older adults in the U.S.,” said Camila Manrique-Acevedo, MD, associate professor of medicine. “Weight loss, physical activity, antihypertensive therapy and lipid-lowering drugs have shown variable effectiveness at improving blood vessel function and reducing arterial stiffness. But additional approaches are needed to improve vascular health in older adults.”
The study first compared blood vessel function and stiffness in 18 healthy human patients — average age of 25 — with 18 patients who averaged 61 years old. They found the older patients had impaired endothelial function and increased aortic stiffness when compared to the younger patients.
“Our findings in young and older adults confirm previous clinical data demonstrating the impact of aging on blood vessel function and arterial stiffness,” Manrique-Acevedo said. “Importantly, we were able to replicate this data in a rodent model.”
In order to investigate the effects of Empa on vascular aging, 72-week-old male mice were divided into two groups. Twenty-nine were fed for six weeks with a diet enriched with Empa, while the other half were given standard food. After analyzing both groups six weeks later, researchers discovered the mice treated with Empa experienced improved blood vessel function, reduced arterial stiffness and other vascular benefits.
“To our knowledge, this is the first study to examine the potential role of SGLT2 inhibition in reversing vascular aging,” Manrique-Acevedo said. “And our findings highlight the need for further clinical investigations to determine the potential role of SGLT2 inhibition as a therapeutic tool to delay or reverse vascular aging in humans.”
The entire MU research team consisted of Jaume Padilla, PhD, associate professor of nutrition and exercise physiology and co-corresponding author of this work; Luis Martinez-Lemus, DVM, PhD, professor of medical pharmacology and physiology, and R. Scott Rector, PhD, associate professor of nutrition. It also included postdoctoral fellows Rogerio Soares, PhD, Francisco Ramirez-Perez, PhD, Thaysa Ghiarone, PhD, and Francisco Cabral-Amador, PhD; research specialist Mariana Morales Quinones; assistant research professors Christopher Foote, PhD, and Neekun Sharma, PhD; and graduate students James A. Smith and Gavin Power.
View original article here Source